A Regulatory Shift Sparks a Rally for Hims & Hers

Hims & Hers shares jump 14% after Health Secretary hints at FDA review of peptide restrictions, offering a lifeline amid legal and regulatory challenges.

Shares of telehealth provider Hims & Hers Health recorded their most significant single-day advance in months on Monday, fueled by unexpected regulatory commentary from U.S. Health Secretary Robert F. Kennedy Jr. This development offers a potential reprieve for the company, which has been navigating a challenging landscape of litigation and regulatory scrutiny.

Financial Performance and Cautious Guidance

Despite the recent stock pressure, the company's operational foundation appears robust. For the full year 2025, revenue surged 59% to $2.35 billion, supported by a subscriber base that grew to 2.5 million. The business maintains a strong gross margin of 73.8%.

However, management's outlook for 2026 has introduced caution. Growth is projected to slow to approximately 15%. A significant headwind is expected in the weight loss segment, which is forecast to negatively impact first-quarter 2026 revenue by about $65 million. The company's long-term target of reaching $6.5 billion in annual revenue by 2030 remains, though it is contingent on maintaining access to compounded semaglutide.

Legal and Regulatory Challenges Mount

The rally comes at a pivotal moment for Hims & Hers. The company faces a dual-front assault from both industry and regulators. Pharmaceutical giant Novo Nordisk has filed a patent infringement lawsuit, seeking a permanent ban on the sale of Hims & Hers' compounded semaglutide products. Concurrently, the Food and Drug Administration (FDA) has initiated tighter controls on mass-marketed GLP-1 agonist drugs.

The Department of Health has referred the matter to the Department of Justice for potential violations of the Food, Drug, and Cosmetic Act. This regulatory pressure has weighed heavily on the stock, which has lost more than three-quarters of its value since its 52-week high of $70.43.

Analyst sentiment has cooled in response. Deutsche Bank reduced its price target from $42 to $31, describing the company as "under siege." The consensus rating among analysts is a "Hold," though the average price target of $26.57 suggests a potential upside of over 60% from recent levels.

A Potential Lifeline in Peptide Regulation

The catalyst for Monday's nearly 14% share price jump, which closed at $16.48, was commentary from Health Secretary Kennedy. In a podcast interview, he indicated the FDA is reviewing the status of roughly 14 peptides currently restricted for use by U.S. compounding pharmacies. Their approval would allow companies like Hims & Hers to legally manufacture these compounds without risk of regulatory action.

Hims & Hers is strategically positioned for this opportunity, having acquired a peptide production facility in California in 2025. Kennedy also referenced an existing "gray market" through which consumers currently obtain peptides—a customer base Hims & Hers could potentially capture with legal authorization.

Global Expansion as a Strategic Counterweight

Alongside its domestic challenges, the company is aggressively pursuing international growth. It plans to acquire Eucalyptus, a digital health provider operating in Australia, the United Kingdom, and Germany, by mid-2026. The deal, valued at up to $1.15 billion, would bring in a business already generating over $450 million in annual revenue.

The central question for investors is whether this global expansion can offset pressures in the critical U.S. market. While Kennedy's peptide initiative could unlock a new product category, it remains to be seen if that will be sufficient to compensate for losses in the GLP-1 segment and fund a multi-billion dollar acquisition simultaneously. The coming months will be decisive.